2014
DOI: 10.1248/cpb.c13-01004
|View full text |Cite
|
Sign up to set email alerts
|

Fabrication of Solid Collagen Nanoparticles Using Electrospray Deposition

Abstract: Collagen is a promising biomaterial for drug delivery due to advantages including high biocompatibility and biodegradable property. However, transforming collagen into solid nanoparticles is difficult, although the solid dosage form is advantageous for some administration routes including pulmonary and oral drug delivery. In this study, collagen solid nanoparticles are prepared in one-step using electrospray deposition under ambient temperature and pressure conditions. Although collagen molecules formed micron… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(17 citation statements)
references
References 27 publications
0
16
0
1
Order By: Relevance
“…Due to collagen’s biocompatibility and low antigenicity, collagen-based nanoparticles have been used for the delivery of pharmaceuticals such as theophylline, retinol, tretinoin, and lidocaine [ 13 , 50 , 51 ]. Collagen is capable of resembling the microenvironment of some tumors allowing collagen nanoparticles to effectively infiltrate the areas and deliver anticancer therapeutics [ 52 ].…”
Section: Categories Of Protein Materialsmentioning
confidence: 99%
“…Due to collagen’s biocompatibility and low antigenicity, collagen-based nanoparticles have been used for the delivery of pharmaceuticals such as theophylline, retinol, tretinoin, and lidocaine [ 13 , 50 , 51 ]. Collagen is capable of resembling the microenvironment of some tumors allowing collagen nanoparticles to effectively infiltrate the areas and deliver anticancer therapeutics [ 52 ].…”
Section: Categories Of Protein Materialsmentioning
confidence: 99%
“…Several types of natural polymers, such as chitosan (Songsurang et al, 2011), alginate (Park et al, 2012), cellulose (Huang et al, 2012), or collagen (Nagarajan et al, 2014), as well as synthetic PLGA (Nath et al, 2013), PCL (Hwang et al, 2008), and polystyrene (PS) (Zheng et al, 2006) have been successfully electrosprayed to generate nano/micro-particulate systems.…”
Section: Non-computer-assisted Approachesmentioning
confidence: 99%
“…Animal studies on DOX-chitosan. Clinical studies (mainly lung and breast cancer): chitosan NPs loaded with curcumin, cisplatin or ascorbate [ 77 , 176 ] Collagen Conjugation with metal NPs, high biocompatibility, suitable for inhalation, controlled release Delivery of collagenase desireable in cancer—not possible with collagen, difficult particle fabrication Research: silver NP stabilized with collagen [ 177 , 178 ] Alginate Mucoadhesive, pH sensitive, oral delivery, suitable for micelles, stabilizer for metal NPs Unknown toxicity, need stabilizers Preclinical studies: magnetic chitosan/alginate- curcumin NP, exemestane-ALG-NPs, paclitaxel-loaded ALG-NP [ 155 , 156 ] Cellulose pH triggered release, completely biodegradable, oral administration, increase drug solubility Difficult fabrication, aggregation due to hydrophylic nature, no release in acidic pH (GC), insufficient knowledge about interaction with cells and tissues Approved: carboxymethyl cellulose. Clinical Trial: eethylcellulose + cetuximab [ 76 , 179 , 180 ] Metal Se Antioxidant, anti-inflammatory properties, anticancer activity, dual delivery of therapeutics like siRNA + cisplatin, curcumin SeNPs Dual role in cancerogenesis and drug delivery—might also produce radicals, possible epigenetical modifications Only in vitro cell studies [ 167 , 181 , 182 ] Au High surface to volume ratio, stable, ideal plasmon resonance for therapeutic applications like photothermal and photodynamic therapy, good biosafety profile, high permeability, scalable Limitations regarding bioavailability of drugs, possible cytotoxicity depending on shape and size, changes in gene expression Approval: DOX-AuNP, clinical trial: oxaliplatin-platinium-AuNP [ 183 ] …”
Section: Np-based Gi Carcinoma Therapiesmentioning
confidence: 99%